(Q44480405)

English

Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

0 references

viral hepatitis

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

author name string

R Navarro

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

E Vilarrasa

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

P Herranz

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

X Bordas

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

J M Carrascosa

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

R Taberner

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

M Ferrán

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

M García-Bustinduy

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

A Romero-Maté

10

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

R Pedragosa

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

A García-Diez

12

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

E Daudén

13

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

language of work or name

0 references

publication date

1 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

British Journal of Dermatology

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

168

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

609-616

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Etanercept Therapy in Patients with Psoriasis and Concomitant HCV Infection

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Safety of anti-tumour necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Interleukin-12 in the treatment of chronic hepatitis B and C.

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

The prevention of infection-associated cancers

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Hepatitis B virus infection--natural history and clinical consequences

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Studies of interleukin-12 in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Etanercept and chronic infection by HCV and HBV

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Safety and efficacy study on etanercept in patients with plaque psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FBJD.12045

21 January 2018

Identifiers

10.1111/BJD.12045

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44480405&oldid=2025303651"